{"createdAt":"8/2/2020, 2:33:52 PM","timestamp":1596393232901,"Company ID number":"614","DMX_ISSUER_NAME":"China Resources Double-crane Pharmaceutical Co., Ltd.","DMX_ISSUER_ID":"IID000000002141534","Country of Classification":"CHINA","name":"China Resources Double-Crane Pharmaceutical Co Ltd ","code":"600062","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"华润双鹤药业股份有限公司_冯毅","group":"board","name":"冯毅","title":"董事长,董事","isMale":true,"age":"58","degree":"硕士","salary":"212.7万","stockAmount":"-","description":"冯毅:男,1962年4月出生,持有中共中央党校硕士研究生学历、北京大学高级管理人员工商管理专业硕士学位。曾任中共中央组织部处长,华润集团人事部副总经理,华润雪花啤酒(盘锦)公司副总经理,华润置地(北京)公司副总经理,珠海华润银行首席人力资源官、高级副行长。现任华润医药集团高级副总裁,华润三九医药股份有限公司监事,华润双鹤药业股份有限公司监事,东阿阿胶股份有限公司监事。","lastUpdated":"2018-12-15"},{"id":"华润双鹤药业股份有限公司_于顺廷","group":"board","name":"于顺廷","title":"董事","isMale":true,"age":"57","degree":"硕士","salary":"284.8万","stockAmount":"-","description":"于顺廷先生,1963年5月出生,沈阳药科大学药物化学专业,硕士学位,高级工程师。曾任中国医药研究开发中心实习研究员,北京制药厂制剂研究所副所长、所长,北京双鹤药业股份有限公司(现为“华润双鹤药业股份有限公司”)党委委员、副总裁、常务副总裁。现任华润双鹤药业股份有限公司党委副书记、总裁。","lastUpdated":"2020-07-24"},{"id":"华润双鹤药业股份有限公司_翁菁雯","group":"board","name":"翁菁雯","title":"董事","isMale":false,"age":"44","degree":"硕士","salary":"0.00","stockAmount":"-","description":"翁菁雯女士:女,1976年1月出生,持有浙江大学经济学学士及中国香港科技大学工商管理硕士学位,曾任普华永道中天会计师事务所审计和商业咨询部高级审计师、华润燃气(集团)有限公司内审部总经理、审计总监、战略总监、华润(集团)有限公司战略管理部副总监等职务。现任华润医药集团有限公司党委委员、副总裁、首席财务官。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_邓荣辉","group":"board","name":"邓荣辉","title":"董事","isMale":true,"age":"49","degree":"硕士","salary":"0.00","stockAmount":"-","description":"邓荣辉先生:男,1971年6月出生,清华大学工学学士学位及中国香港大学工商管理学硕士学位,工程师资格。曾任华润营造(控股)有限公司董事、董事助理总经理,华润物业有限公司副总经理。现任华润(集团)有限公司战略管理部助理总监。","lastUpdated":"2019-09-07"},{"id":"华润双鹤药业股份有限公司_韩跃伟","group":"board","name":"韩跃伟","title":"董事","isMale":true,"age":"52","degree":"硕士","salary":"0.00","stockAmount":"-","description":"韩跃伟先生:男,1968年3月出生,持有清华大学土木工程系建筑管理学士学位和清华大学建筑经济与管理硕士学位,曾任深圳市建筑工务署市政处处长、华润集团深圳区域工委书记、华润置地有限公司副总裁、华润医疗控股有限公司行政总裁、华润健康集团有限公司党委副书记、总经理等职务。现任华润医药控股有限公司党委书记、华润医药集团有限公司执行董事、首席执行官。","lastUpdated":"2019-12-13"},{"id":"华润双鹤药业股份有限公司_刘文涛","group":"board","name":"刘文涛","title":"董事","isMale":true,"age":"48","degree":"硕士","salary":"0.00","stockAmount":"-","description":"刘文涛先生:男,出生于1972年5月,北京大学经济学硕士学位。曾任合宜咨询公司顾问,高级顾问,韬睿咨询公司资深顾问,咨询总监,美世咨询公司华南区总经理,华润集团人力资源部副总监,华润医药集团有限公司副总经理兼首席人力资源官。现任华润集团人力资源部高级副总监,华润三九董事。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_郭巍","group":"board","name":"郭巍","title":"董事","isMale":false,"age":"44","degree":"硕士","salary":"0.00","stockAmount":"-","description":"郭巍女士,1976年3月出生,对外经济贸易大学经济学学士学位,北京大学研究生院法学硕士学位。曾任华润轻纺投资发展有限公司内审部高级经理,华润创业有限公司内审部经理,华润(集团)有限公司审计监察部经理、高级审计师,财务部高级经理、助理总监。现任华润(集团)有限公司财务部副总监,华润三九医药股份有限公司、华润双鹤药业股份有限公司董事。郭巍女士于2019年5月29日获委任为华润医药集团有限公司非执行董事。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_康彩练","group":"board","name":"康彩练","title":"独立董事","isMale":true,"age":"46","degree":"博士","salary":"15.00万","stockAmount":"-","description":"康彩练先生,1974年8月出生,同济医科大学内科学博士学位,主任药师。曾任国家食品药品监督管理局药品评审中心高级审评师。现任鸿商资本股权投资有限公司董事总经理。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_ZhengWei","group":"board","name":"ZhengWei","title":"独立董事","isMale":true,"age":"60","degree":"博士","salary":"15.00万","stockAmount":"-","description":"Zheng Wei先生,1960年7月出生,美国国籍,纽约大学经济学博士学位。曾是上海市体委运动员。曾任美世咨询纽约总部咨询顾问、高级咨询顾问,美世咨询(中国)有限公司全球合伙人和中国区合伙人,上海皓羿企业管理咨询有限公司合伙人。现任上海羿携企业管理咨询有限公司合伙人,中远海运特种运输股份有限公司独立董事。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_文光伟","group":"board","name":"文光伟","title":"独立董事","isMale":true,"age":"57","degree":"博士","salary":"15.00万","stockAmount":"-","description":"文光伟先生,1963年3月出生,中国人民大学管理学博士,中国注册会计师。1983年8月至1988年9月,担任中国人民大学会计系助教,1988年9月至1989年12月,担任中国人民大学会计系讲师,1989年12月至1991年6月,担任中国香港普华会计公司审计部会计,1991年6月至1994年8月,担任中国人民大学会计系讲师,1998年8月至2001年12月,就读于中国人民大学会计系审计方向博士研究生,1994年8月至2015年3月,担任中国人民大学商学院会计系副教授、硕士研究生导师。现任华泰柏瑞基金管理有限公司、环能国际控股有限公司、北京万东医疗科技股份有限公司独立董事。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_刘俊海","group":"board","name":"刘俊海","title":"独立董事","isMale":true,"age":"51","degree":"博士","salary":"15.00万","stockAmount":"-","description":"刘俊海,男,生于1969年,博士,博士生导师。曾任中国社会科学院法学所所长助理兼所务办公室主任、研究员,泰信基金管理公司、株冶火炬、工大首创、宏源证券、大方数码独立董事,重工源畅(港交所上市)、中国外运(港交所上市)独立非执行董事。现任中国人民大学教授、商法研究所所长,兼任启迪桑德、华润双鹤、中国中投证券有限责任公司独立董事,恒泰艾普董事。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_吴峻","group":"supervisoryCommittee","name":"吴峻","title":"监事会主席","isMale":true,"age":"58","degree":"硕士","salary":"0.00","stockAmount":"-","description":"吴峻:男,1962年8月出生,持有天津大学机械工程类硕士学位,美国旧金山大学工商管理硕士学位。曾任华润机械五矿(集团)有限公司董事、总经理,华润集团企业开发部副总经理,华润投资开发有限公司董事、副总经理,华润集团审计部副总经理。现任华润医药集团高级副总裁,同时担任华润三九医药股份有限公司董事、华润双鹤药业股份有限公司监事、东阿阿胶股份有限公司董事。","lastUpdated":"2018-06-26"},{"id":"华润双鹤药业股份有限公司_陈宏","group":"supervisoryCommittee","name":"陈宏","title":"监事","isMale":true,"age":"60","degree":"本科","salary":"0.00","stockAmount":"-","description":"陈宏先生,1960年10月出生,助理工程师,曾于中共北京市市委党校经济管理专业本科班学习。曾任北京第二制药厂(现为华润赛科药业有限责任公司)副厂长,北京赛科药业有限责任公司(现为华润赛科药业有限责任公司)党委书记、董事长,北京医药集团有限责任公司副总经理,华润医药集团有限公司副总裁等职务。曾获“首都五一劳动奖章”、“北京市劳动模范”、“全国五一劳动奖章”等奖项。现任华润医药控股有限公司党委委员、纪委书记,华润医药集团有限公司高级副总裁。","lastUpdated":"2018-11-14"},{"id":"华润双鹤药业股份有限公司_陶然","group":"supervisoryCommittee","name":"陶然","title":"监事","isMale":true,"age":"55","degree":"硕士","salary":"0.00","stockAmount":"-","description":"陶然:男,1965年10月出生,持有上海交通大学工学学士、北京航空航天大学经济学硕士学位。曾任中国华润总公司(现为中国华润有限公司)进口一部副科长,华润纺织集团有限公司投资部高级经理、战略部总经理、公司副总经理,华润医药集团有限公司战略发展部高级总监、战略发展部总经理。现任华润医药集团有限公司助理总裁。","lastUpdated":"2019-05-30"},{"id":"华润双鹤药业股份有限公司_闫丽丽","group":"supervisoryCommittee","name":"闫丽丽","title":"职工监事","isMale":false,"age":"46","degree":"本科","salary":"26.86万","stockAmount":"-","description":"闫丽丽女士,1974年7月出生,全国高等教育自学考试法律专业本科学历。曾任北京制药厂工会干事,北京双鹤药业股份有限公司工会主管、工会事务经理。现任华润双鹤药业股份有限公司工会副主席。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_韩朔","group":"supervisoryCommittee","name":"韩朔","title":"职工监事","isMale":false,"age":"42","degree":"硕士","salary":"63.11万","stockAmount":"-","description":"韩朔女士,1978年12月出生,中国人民大学劳动经济学专业硕士学历。曾任北京双鹤药业股份有限公司干部监管部主管,北京双鹤现代医药技术有限责任公司党支部副书记,北京双鹤药业股份有限公司(北京工业园)人力资源部经理,华润双鹤药业股份有限公司生产管理中心人力资源部总经理。现任华润双鹤药业股份有限公司人力资源部总经理、党委组织部部长、总部管理党总支书记。","lastUpdated":"2018-06-23"},{"id":"华润双鹤药业股份有限公司_于顺廷","group":"manager","name":"于顺廷","title":"总裁,常务副总裁","isMale":true,"age":"57","degree":"硕士","salary":"284.8万","stockAmount":"-","description":"于顺廷先生,1963年5月出生,沈阳药科大学药物化学专业,硕士学位,高级工程师。曾任中国医药研究开发中心实习研究员,北京制药厂制剂研究所副所长、所长,北京双鹤药业股份有限公司(现为“华润双鹤药业股份有限公司”)党委委员、副总裁、常务副总裁。现任华润双鹤药业股份有限公司党委副书记、总裁。","lastUpdated":"2020-07-24"},{"id":"华润双鹤药业股份有限公司_范彦喜","group":"manager","name":"范彦喜","title":"董事会秘书,副总裁","isMale":true,"age":"56","degree":"硕士","salary":"204.0万","stockAmount":"-","description":"范彦喜先生,1964年2月出生,首都经济贸易大学研究生学历,高级会计师。曾任郑州纺织机械厂财务科财务副组长、财务部会计副科长、财务部副部长、部长、副总会计师,中国纺织机械(集团)有限公司财务部副部长,中国华源生命产业有限公司副总会计师兼财务部部长,北京医药集团有限责任公司总会计师、财务部经理,华润万东医疗装备股份有限公司(更名为北京万东医疗科技股份有限公司)监事,华润双鹤药业股份有限公司董事。现任华润双鹤药业股份有限公司董事会秘书、副总裁、党委委员。","lastUpdated":"2018-06-26"},{"id":"华润双鹤药业股份有限公司_倪军","group":"manager","name":"倪军","title":"副总裁","isMale":true,"age":"58","degree":"硕士","salary":"191.2万","stockAmount":"-","description":"倪军先生,1962年2月出生,中南财经政法大学工商管理专业,硕士学位。曾任北京制药厂片剂车间技术员、工艺员、副主任,团委副书记,厂办副主任、主任,北京双鹤药业股份有限公司董事会秘书、副总裁。现任华润双鹤药业股份有限公司副总裁、党委副书记、纪委书记。","lastUpdated":"2018-06-26"},{"id":"华润双鹤药业股份有限公司_吴文多","group":"manager","name":"吴文多","title":"副总裁","isMale":true,"age":"47","degree":"本科","salary":"220.5万","stockAmount":"-","description":"吴文多先生,1973年10月出生,武汉大学生物化学专业,学士学位。曾任北京赛科昌盛医药有限责任公司业务部经理、总经理助理兼策划部经理、人力资源部经理、副总经理、常务副总经理、总经理,北京赛科药业有限责任公司营销部经理、副总经理、党委副书记、总经理,华润赛科药业有限责任公司党委副书记。现任华润赛科药业有限责任公司总经理、党委书记,华润双鹤药业股份有限公司副总裁。","lastUpdated":"2018-06-26"},{"id":"华润双鹤药业股份有限公司_陆文超","group":"manager","name":"陆文超","title":"副总裁","isMale":true,"age":"44","degree":"硕士","salary":"186.9万","stockAmount":"-","description":"陆文超先生,1976年7月出生,沈阳药科大学药物化学专业,硕士学位。曾任北京双鹤药业股份有限公司研究院合成室课题负责人,总裁办公室副主任,北京工业园总经理助理,生产管理中心技术创新部总经理兼任北京工业园副总经理,总裁助理。现任华润双鹤药业股份有限公司副总裁,兼任营销管理中心总经理,北京及儿科业务部总经理,代理业务部总经理。","lastUpdated":"2018-06-26"}],"companyName":"华润双鹤药业股份有限公司","province":"北京市","englishName":"China Resources Dubl-Crne Phrmctl Co Ltd","industry":"医药生物 — 化学制药","website":"www.dcpc.com","mainBusiness":"主要从事药品开发、制造和销售","productsName":["复方利血平氨苯蝶啶","苯磺酸氨氯地平片","缬沙坦胶囊","厄贝沙坦分散片","硝苯地平缓释片","匹伐他汀钙片","格列喹酮片","胞磷胆碱钠片","注射用牛肺表面活性剂","丙戊酸镁缓释片","软袋","内封式聚丙烯输液袋"],"actualController":"国务院国有资产监督管理委员会","actualControllerSharePercentage":"31.82%","registeredCapital":"10.43亿元","employeeAmount":"12276","phone":"86-010-64398099","location":"北京市朝阳区望京利泽东二路1号","chineseDescription":"华润双鹤药业股份有限公司是中国首家通过GMP认证的医药公司,主营业务涵盖新药开发、药物制造、医药经营及制药装备等领域的大型现代化医药企业.公司已战略性地构建了四大经营发展支柱:全国最大的输液供应基地、中国领先的全合成抗菌药生产基地、天然药物创新基地、全国性的药品销售服务体系,在心血管、大输液、抗生素、胃药、保健品等领域建立了专业优势,拥有包括北京降压0号、利复星、奥复星、温胃舒、养胃舒、北京蜂王精等在内的一系列名牌产品。","foundedDate":"1997-05-16","goPublicDate":"1997-05-22","companyHistory":"华润双鹤药业股份有限公司(以下简称“公司”或“本公司”)系经北京市人民政府京政办函(1997)58号文批准，由北京制药厂(已被北京医药集团有限责任公司吸收合并)、北京永好科技发展有限责任公司、北京市医药总公司(现为北京医药集团有限责任公司，以下简称“北药集团”)、北京市国有资产经营有限责任公司、中国南方证券有限公司及北京科梦嘉生物技术开发有限责任公司共同发起，以募集方式成立的股份公司。经中国证券监督管理委员会证监发(1997)170号文批准，本公司于1997年5月6日在上海证券交易所上市发行了人民币普通股4,230万股，另向职工配售了470万股。发行后，本公司注册资本为14,700万元，由北京市工商行政管理局核发了注册号为1100001510319号的营业执照。公司法定代表人：李福祚。\n　　公司实际控制人：中国华润总公司。\n　　根据股东大会决议，本公司1999年度向全体股东每10股送2股红股及每10股转增3股；根据股东大会决议和中国证券监督管理委员会证监公司字[1999]44号文批准，本公司1999年度配股1,465万股；根据股东大会决议，本公司2000年度向全体股东每10股转增3股；根据股东大会决议及中国证券监督管理委员会证监公司字[2001]54号文批准，本公司2001年度配股3,359.40万股；根据2001年度股东大会决议，本公司以2001年末总股本向全体股东每10股转增3股。经上述送配和转增股本后，本公司总股本变更为44,107.57万股。\n　　根据本公司2006年3月28日召开的股权分置改革相关股东会议决议，实施股权登记日在册的公司流通股股东(2006年4月4日)，每持有10股流通股将获得非流通股股东支付的3.2股股票，非流通股股东支付的股份总数为59,477,184股。该方案完成后本公司的股份总数维持不变。\n　　根据股东大会决议和中国证券监督管理委员会证监许可[2008]413号文批准，本公司于2008年4月29日非公开发行股票35,337,590股，发行后本公司总股本变更为476,413,290股。\n　　根据股东大会决议，本公司以2008年末总股本476,413,290股为基础向全体股东每10股派送红股2股，经上述送股后，本公司总股本变更为571,695,948股。截至2012年12月31日，全部为无限售条件流通股。\n　　经国务院国有资产监督管理委员会批准，北京国有资本经营管理中心将其持有的北药集团1%的国有股权无偿划转给中国华润总公司。股权划转完成后，中国华润总公司合计持有北药集团51%的股权，成为本公司的最终控制人。截至2012年12月31日，北药集团持有本公司的股份为280,820,611股，持股比例为49.12%。\n　　2012年经第一次临时股东大会会议审议通过，本公司由“北京双鹤药业股份有限公司”变更为“华润双鹤药业股份有限公司”。变更事项已于2012年3月14日经北京市工商行政管理局核准。鉴于公司名称发生变化，经本公司申请，并经上海证券交易所核准，本公司证券简称自2012年3月27日起变更为“华润双鹤”，证券代码“600062”不变。\n　　截止2013年12月31日，本公司的股本总数为57,169.5948万股，注册资本为57,169.5948万元。注册及总部办公地址：北京市朝阳区望京利泽东二路1号。收起▲","shareholders":[{"organizationId":"00010205","holderName":"北京医药集团有限责任公司","totalShare":"6.26亿","sharePercentage":"59.99%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"4385.65万","sharePercentage":"4.20%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1778.03万","sharePercentage":"1.70%"},{"organizationId":"","holderName":"王开平","totalShare":"809.34万","sharePercentage":"0.78%"},{"organizationId":"","holderName":"白秀平","totalShare":"676.09万","sharePercentage":"0.65%"},{"organizationId":"","holderName":"中国人寿保险股份有限公司-传统-普通保险产品-005L-CT001沪","totalShare":"653.05万","sharePercentage":"0.63%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"499.04万","sharePercentage":"0.48%"},{"organizationId":"","holderName":"王开斌","totalShare":"430.20万","sharePercentage":"0.41%"},{"organizationId":"","holderName":"汇添富基金管理股份有限公司-社保基金四二三组合","totalShare":"400.01万","sharePercentage":"0.38%"},{"organizationId":"","holderName":"何东翰","totalShare":"400.00万","sharePercentage":"0.38%"}],"englishDescription":"CHINA RESOURCES DOUBLE-CRANE PHARMACEUTICAL CO.,LTD. is a China-based company principally engaged in the development, manufacture and distribution of pharmaceuticals. The Company's main businesses are classified into three segments: Chronic Disease segment, Specialist segment and Infusion segment. Chronic Disease segment mainly provides products for lowering blood pressure, blood fat and blood glucose. Specialist segment mainly involves in the research, development and distribution of pharmaceuticals targeting six areas, including cardiovascular and cerebrovascular, pediatrics, kidney disease, mental/nerve, anesthesia and analgesia and respiratory areas. Infusion segment various types of infusion products, such as basic infusion, therapeutic infusion and nutritional. The Company distributes its products mainly in domestic market.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"15.14","Price to sales (ttm)":"1.70","Price to book (mrq)":"1.71","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.66","Lt debt to equity (mrq)":"0.00","Return on investment (ttm)":"11.50","Return on equity (ttm)":"8.98","Income statement":{},"Balance sheet":{},"Cash flow":{"Cash receipts":"9,289.99","Cash payments":"(1,726.77)","Cash taxes paid":"(1,210.90)","Changes in working capital":"(4,912.53)","Cash from operating activities":"1,439.79","Capital expenditures":"(241.65)","Other investing cash flow items, total":"(827.65)","Cash from investing activities":"(1,069.30)","Financing cash flow items":"(8.60)","Total cash dividends paid":"(299.16)","Issuance (retirement) of debt, net":"(217.10)","Cash from financing activities":"(524.86)","Foreign exchange effects":"(0.03)","Net change in cash":"(154.40)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"14.53","52 Week High":"15.83","52 Week Low":"11.92","Pricing date":"","10 Day Average Trading Volume":"20.02","Market Capitalization":"15,158.24","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"241.96","Beta":"1.07","1 Day Price Change":"2.40","13 Week Price Return (Daily)":"13.69","26 Week Price Return (Daily)":"5.52","5 Day Price Return (Daily)":"6.68","52 Week Price Return (Daily)":"14.95","Year To Date Price Return (Daily)":"11.34","Month to Date Price Return (Daily)":"9.91","Price Relative to S&P500 (4 Week)":"3.05","Price Relative to S&P500 (13 Week)":"-1.76","Price Relative to S&P500 (26 Week)":"-5.11","Price Relative to S&P500 (52 Week)":"1.02","Price Relative to S&P500 (YTD)":"2.60"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"1.01","EPS excl. Extra Items (TTM)":"0.96","EPS Normalized (Annual)":"1.08","Revenue per Share (Annual)":"8.99","Revenue per Share (TTM)":"8.56","Book Value (Per Share Annual)":"8.25","Book Value (Per Share Quarterly)":"8.51","Tangible Book Value (Per Share Annual)":"5.87","Tangible Book Value (Per Share Quarterly)":"6.13","Cash Per Share (Per Share Annual)":"2.58","Cash Per Share (Per Share Quarterly)":"2.80","Cash Flow (Per Share Annual)":"1.36","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.30","Dividends (Per Share TTM)":"0.30","EBITD (Per Share TTM)":"1.18","EPS Basic excl. Extra Items (Annual)":"1.01","EPS Basic excl. Extra Items (TTM)":"0.96","EPS incl. Extra Items (Annual)":"1.01","EPS incl. Extra Items (TTM)":"0.96","Free Cash Flow (Per Share TTM)":"0.79","Dividend (Per Share 5Y)":"0.17"},"Valuation":{"P/E excl. Extra Items (Annual)":"14.37","P/E excl. Extra Items (TTM)":"15.14","P/E Normalized (Annual)":"13.50","Price to sales (Annual)":"1.62","Price to sales (TTM)":"1.70","Price to Tangible Book (Annual)":"2.47","Price to Tangible Book (Quarterly)":"2.37","Price to Free Cash Flow (Per Share Annual)":"16.86","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"18.33","Price to Book (Annual)":"1.76","Price to Book (Quarterly)":"1.71","P/E Basic excl. Extra Items (TTM)":"13.21","P/E excl. Extra Items High (TTM)":"25.54","P/E excl. Extra Items Low (TTM)":"12.20","P/E incl. Extra Items (TTM)":"15.14","Net Debt (Interim)":"-2,863.62","Net Debt (Annual)":"-2,625.35","Dividend Yield (5Y)":"1.12","Dividend Yield":"2.09","Current Dividend Yield (TTM)":"2.09"},"Financial Strength":{"Free Cash Flow (Annual)":"898.98","Current Ratio (Annual)":"2.58","Net Interest coverage (Annual)":"--","Long Term Debt/Equity (Annual)":"0.00","Payout Ratio (Annual)":"30.06","Quick Ratio (Annual)":"2.09","Total Debt/Total Equity (Annual)":"0.83","Current EV/Free Cash Flow (Annual)":"14.28","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"2.69","Long Term Debt/Equity (Quarterly)":"0.00","Quick Ratio (Quarterly)":"2.23","Total Debt/Total Equity (Quarterly)":"0.66","Free Cash Flow (TTM)":"826.81","Net Interest Coverage (TTM)":"--","Payout Ratio (TTM)":"31.68"},"Margins":{"Gross Margin (Annual)":"62.86","Gross Margin (TTM)":"61.82","Net Profit Margin % (Annual)":"11.37","Net Profit Margin (TTM)":"11.31","Operating Margin (Annual)":"13.46","Operating Margin (TTM)":"13.45","Pretax Margin (TTM)":"13.39","Pretax Margin (Annual)":"13.45","Operating Margin (5Y)":"14.78","Pretax Margin (5Y)":"15.04","Free Operating Cash Flow/Revenue (5Y)":"11.23","Free Operating Cash Flow/Revenue (TTM)":"9.26","Gross Margin (5Y)":"58.78","Net Profit Margin (5Y)":"12.53"},"Management Effectiveness":{"Return on Assets (Annual)":"9.88","Return on Equity (TTM)":"8.98","Return on Average Equity (Annual)":"12.83","Return on Average equity (TTM)":"11.74","Return on Investment (Annual)":"12.57","Return on Investment (TTM)":"11.50","Return on Average Assets (5Y)":"9.63","Return on Average Equity (5Y)":"11.96","Return on Investment (5Y)":"11.82","Asset Turnover (Annual)":"0.87","Asset Turnover (TTM)":"0.79","Inventory Turnover (Annual)":"3.29","Inventory Turnover (TTM)":"3.53","Net Income/Employee (Annual)":"87,824.77","Net Income/Employee (TTM)":"82,296.83","Receivables Turnover (Annual)":"8.32","Receivables Turnover (TTM)":"6.25","Revenue/Employee (Annual)":"772,543.00","Revenue/Employee (TTM)":"727,447.80"},"Growth":{"Revenue Growth (Quarterly YoY)":"-17.12","Revenue Growth Rate (5Y)":"12.73","EPS Growth (Quarterly YoY)":"-16.46","EPS Growth (TTM YoY)":"0.37","EPS Growth Rate (5Y)":"2.48","Dividend Growth Rate (3Y)":"64.13","Revenue Growth (TTM YoY)":"2.41","Revenue Growth (Per Share 5Y)":"7.51","Revenue Growth Rate (3Y)":"19.52","EPS Growth Rate (3Y)":"13.89","Book Value Growth Rate (Per Share 5Y)":"1.98","Tangible Book Value Total Equity CAGR (5Y)":"1.75","Capital Spending growth rate 5 year":"7.59","EBITDA CAGR (5Y)":"8.64","EBITDA Interim CAGR (5Y)":"6.72","Free Operating Cash Flow CAGR (5Y)":"58.73","Total Debt CAGR (5Y)":"39.75","Net Profit Margin Growth Rate (5Y)":"-4.53"},"Income Statement":{"Revenue (Annual)":"9,380.99","Revenue (TTM)":"8,930.15","EBITD (Annual)":"1,652.32","EBITD (TTM)":"1,227.50","Earnings Before Taxes (Annual)":"1,261.80","Earnings Before Taxes (TTM)":"1,195.34","Net Income to Common (Annual)":"1,055.12","Net Income to Common (TTM)":"1,000.96","Earnings Before Taxes Normalized (Annual)":"1,342.27","Net Income Available to Common Normalized (Annual)":"1,123.14","Diluted Normalized EPS excl. Extra Items (TTM)":"1.02"}}}